However, our results also contraindicate the use of PARP inhibitors during 7+3 chemotherapy since olaparib exhibited antagonistic effects toward the killing of both M1/M2 and M4/M5 AML cancer cells by ara-C and idarubicin (Tables S2 and S3). The gene discussed is PARP1; the disease is cancer.